Research
Hormonal
Incretin-based medications (GLP-1 RAs, dual/tri-agonists) achieve high rates of glycemic control (HbA1c ≤ 6.5%) and weight loss, but technically do not constitute 'remission' as defined by the consensus (which requires being off medication), as the effect persists only while taking the drug.
Newer incretin-based medications (like GLP-1 and dual/tri-agonists) are highly effective at lowering blood sugar and promoting weight loss, with some trials showing over 80% of patients reaching normal HbA1c levels. However, this control is dependent on continuing the medication and does not constitute 'remission' in the strict sense of being off all drugs.
GoodQualifiesHIGH confidence
Cases of T2DM 'remission' achieved through incretin-based medications do not technically meet the proposed definition of remission and only persist while patients are keeping their weight loss achievement mostly by actively taking the medication.
Why this rating
Cites major trials (STEP 2, SURPASS-4, SURMOUNT-1).
Source
Remission of type 2 diabetes mellitus
Afif Nakhleh et al. · World Journal of Diabetes · 2024
DOI 10.4239/wjd.v15.i7.1384
narrative_reviewCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Significant weight loss (typically >10%) induced by intensive lifestyle interventions (very low-calorie diets) or metabolic bariatric surgery can induce remission of type 2 diabetes (HbA1c < 6.5% without medication), primarily by reversing ectopic fat accumulation in the pancreas and liver.Strong
- Metabolic bariatric surgery (specifically malabsorptive procedures like Roux-en-Y gastric bypass) offers higher remission rates for Type 2 Diabetes than restrictive procedures (like sleeve gastrectomy), particularly in patients with severe obesity (BMI ≥ 35).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →